Dagmara Gładysz

Dagmara Gładysz

Auto-generated profile, based on publicly available information

Dagmara Gładysz

The University of Rzeszow, Rzeszów, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
JBJoanna Barwacz
Joanna Barwacz
DGDagmara Gładysz
Dagmara Gładysz
MAMagdalena Adamik
Magdalena Adamik
LSLayla Settaf-Cherif
Layla Settaf-Cherif
KMKatarzyna Malinowska
Katarzyna Malinowska
ESElhatra Settaf-Cherif
Elhatra Settaf-Cherif
Introduction: Mobile applications (mHealth) are playing an increasingly important role in promoting healthy lifestyles and supporting patients with chronic diseases. Evidence from evidence-based medicine (EBM) studies indicates that they can support behavioral change, improve clinical parameter control and facilitate contact with the healthcare system. Objective: The aim of this study was to present current scientific evidence on the effectiveness of mobile applications in the field of health, with particular emphasis on behavioral and social effects. Methods: Systematic reviews, meta-analyses and randomized trials on the use of mobile applications for physical activity, weight loss, diabetes control, hypertension and other chronic diseases, as well as for improving adherence to pharmacotherapy recommendations, were included. Reports on data security, digital inequalities and WHO recommendations on mHealth were also analyzed. Results: According to meta-analyses, diabetes management apps lead to a significant reduction in HbA1c (by ~0.5% on average), especially when they are part of integrated clinical care. Apps that remind users to take their medication improve health behaviors related to pharmacotherapy, while those that promote physical activity and diet promote moderate, short-term weight loss and increased physical activity. Interventions using behavior change techniques such as self-monitoring, feedback and reminders are most effective. Positive social effects include increased motivation through support networks and facilitation of telemonitoring, but there are challenges related to data security, digital inequalities and lack of standardization in app quality. Conclusions: Mobile applications have potential as a tool to support the prevention and management of chronic diseases, but their effectiveness is moderate and variable. Further long-term randomized trials and the implementation of quality and safety standards are needed to fully exploit their clinical and social potential.

30 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ESElhatra Settaf-Cherif
Elhatra Settaf-Cherif
LSLayla Settaf-Cherif
Layla Settaf-Cherif
KMKatarzyna Malinowska
Katarzyna Malinowska
JBJoanna Barwacz
Joanna Barwacz
DGDagmara Gładysz
Dagmara Gładysz
MAMagdalena Adamik
Magdalena Adamik
Background: Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, shows promise beyond glycemic control for managing cardiovascular risk factors. Recent studies suggest that tirzepatide may also offer cardiovascular benefits by improving weight, glycemic control, blood pressure, systemic inflammation, and cardiometabolic risk factors. Aim: Our review summarizes the current evidence on tirzepatide’s cardiovascular effects, mechanisms of action, clinical outcomes, and safety profile in populations at increased cardiovascular risk. Methodology: We conducted a narrative literature review of tirzepatide and cardiovascular outcomes using PubMed and Google Scholar. Conclusion: Tirzepatide appears to be a promising therapeutic option for reducing cardiovascular risk, particularly in patients with type 2 diabetes, obesity, and heart failure. Current data support its positive effects on multiple cardiovascular risk factors. However, further confirmation from large clinical trials is needed to fully establish its long-term benefits and safety.

5 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
KMKatarzyna Malinowska
Katarzyna Malinowska
ESElhatra Settaf-Cherif
Elhatra Settaf-Cherif
JBJoanna Barwacz
Joanna Barwacz
MAMagdalena Adamik
Magdalena Adamik
LSLayla Settaf-Cherif
Layla Settaf-Cherif
DGDagmara Gładysz
Dagmara Gładysz
Background: Vitiligo is a chronic skin disorder characterized by the development of hypopigmented or depigmented macules and patches, resulting from the loss of functional melanocytes in the affected areas. It is estimated to affect approximately 0.5% to 4% of the global population. Although the exact etiology remains unclear, vitiligo is considered an acquired, multifactorial condition involving complex interactions. Aim: To summarize current knowledge on vitiligo, focusing on its pathogenesis, clinical presentation, diagnostic principles, and therapeutic strategies. Methodology: Literature review was conducted using PubMed, the Cochrane Library, and Google Scholar databases. Results: Vitiligo is now widely regarded as an autoimmune disorder. Current management centers on immune modulation through topical and systemic agents, phototherapy, and, in selected cases, surgical intervention. Adjunctive measures including camouflage techniques, nutritional optimization, and psychological support play an important role in improving quality of life. Conclusions: Vitiligo results from complex autoimmune and oxidative processes leading to melanocyte destruction. First-line treatment typically includes topical corticosteroids or calcineurin inhibitors, with phototherapy serving as an effective and well-established adjunct. Combination and targeted immunomodulatory therapies, such as JAK inhibitors, represent promising future directions. Despite notable advances, complete and durable repigmentation remains uncommon, highlighting the need for continued research and individualized patient care.

30 December 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
MCMarta Czarnowska
Marta Czarnowska
RSRadosław Sciepuro
Radosław Sciepuro
NCNina Czarnowska
Nina Czarnowska
LSLayla Settaf-Cherif
Layla Settaf-Cherif
KMKatarzyna Malinowska
Katarzyna Malinowska
AZAgnieszka Zaleszczyk
Agnieszka Zaleszczyk
Background: Postpartum depression is a significant mood disorder affecting women during the first year after childbirth. Emerging evidence indicates that gut microbiota may play a meaningful role in its development through inflammatory, metabolic, and neuroendocrine pathways. The purpose of this review is to synthesize current knowledge on gut microbiota alterations during pregnancy and postpartum and to evaluate their potential contribution to postpartum depression, with emphasis on mechanistic links and opportunities for therapeutic modulation. Methodology: This review was conducted by analyzing clinical, mechanistic, and translational studies, using PubMed, the Cochrane Library, and Google Scholar databases, that focused on maternal microbiota composition, postpartum mood disturbances, and microbiota-modulating strategies. Results: The reviewed evidence demonstrates that women with depressive symptoms commonly exhibit reduced levels of anti-inflammatory and short-chain-fatty-acid-producing bacteria and an increased presence of pro-inflammatory taxa. Pregnancy and postpartum are characterized by substantial microbial shifts, including changes in Firmicutes and Bacteroidetes, with postpartum reductions in beneficial genera such as Faecalibacterium and Bacteroides. These alterations may influence inflammation, neurotransmitter metabolism, intestinal barrier function, and stress-axis activity, collectively contributing to depressive risk. Interventions aimed at modulating the maternal microbiota, including dietary strategies and probiotic supplementation, show preliminary potential for reducing depressive symptoms or lowering postpartum depression risk. Conclusions: Overall, current findings suggest that gut microbiota may represent both a biomarker and a modifiable factor in postpartum depression. Microbiota-targeted approaches warrant further investigation to determine their preventive and therapeutic utility in maternal mental health.

9 January 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
JBJoanna Barwacz
Joanna Barwacz
MAMagdalena Adamik
Magdalena Adamik
DGDagmara Gładysz
Dagmara Gładysz
MCMarta Czarnowska
Marta Czarnowska
RSRadosław Sciepuro
Radosław Sciepuro
AZAgnieszka Zaleszczyk
Agnieszka Zaleszczyk
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), play a key role in human health, including protection of the cardiovascular system, support for neurological functions, and influence on anti-inflammatory processes. Despite the known importance of their consumption, the quality and form of supplementation (oil vs. capsules) are raising increasing doubts. One important aspect is the stability of these polyunsaturated fatty acids, as their susceptibility to oxidation may reduce their effectiveness or even lead to the formation of adverse products. In this context, the total oxidation index (TOTOX) is a commonly used marker for assessing the degree of oxidation of fish oils and omega-3 supplements. This article provides a comprehensive review of the scientific literature comparing oil and capsule forms of omega-3 supplements, taking into account criteria such as oxidative parameters (TOTOX, peroxide value, anisidine value), bioavailability, and user preferences. The results indicate that capsules often offer better protection against oxidation during storage (lower TOTOX values) compared to liquid forms. For example, syrup products achieved TOTOX values of ~97 meq/kg at the end of the study, while capsules achieved ~30 meq/kg under similar conditions. In addition, the bioavailability of EPA/DHA depended on the chemical form (triglycerides > ethyl esters) and the delivery system — emulsions or liquid forms showed faster absorption than traditional gel capsules. Based on the data collected, it can be concluded that the choice of omega-3 supplement form should take into account not only the EPA/DHA content, but also the oxidative quality, chemical form, and storage method. For dietary practice, products with a low TOTOX index, adequately protected from light and oxygen, and taken with a meal containing fat to increase absorption are recommended.

9 January 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
DGDagmara Gładysz
Dagmara Gładysz
JBJoanna Barwacz
Joanna Barwacz
MAMagdalena Adamik
Magdalena Adamik
MCMarta Czarnowska
Marta Czarnowska
RSRadosław Sciepuro
Radosław Sciepuro
AZAgnieszka Zaleszczyk
Agnieszka Zaleszczyk
Research objectives: This comprehensive systematic review and meta-analysis aims to critically evaluate the clinical evidence on the effectiveness, feasibility, and cost-effectiveness of wearable technologies in health monitoring and the prevention of lifestyle diseases between 2020 and 2024. The study focuses on two main pillars of innovation: devices for monitoring physical activity and health parameters (smartwatches, fitness bands, continuous glucose monitors) and artificial intelligence (AI)-based data analysis systems that enable early risk detection and personalization of health interventions. In addition, the review analyzes the ethical, legal, social, and implementation (ELSI) barriers that must be overcome to enable the large-scale implementation of wearable technologies in healthcare systems. Methods: A scoping review of scientific literature was conducted in databases including PubMed, Scopus, and Google Scholar, using inclusion criteria that included randomized controlled trials (RCTs), systematic reviews, and meta-analyses published from January 2020 to July 2024. Seven key meta-analyses and twenty RCTs were analyzed in detail, focusing on effect sizes (Hedges' g, standardized mean difference - SMD), adherence rates, and impact on clinical endpoints. The risk of systematic error and regulatory frameworks were also assessed. Main results: Wearable technologies showed moderate to high effectiveness in monitoring health parameters and modifying health-related behaviors. A meta-analysis of interventions using wearable devices to monitor physical activity showed a statistically significant increase in the number of steps per day (weighted mean difference: 1519 steps/day, 95% CI 1096-1942) and moderate to large effect sizes (SMD = 0.449) compared to control groups (Hodkinson et al., 2021; Tang et al., 2020). Continuous glucose monitoring (CGM) has shown particularly high effectiveness in diabetes control. A meta-analysis of 15 RCTs (2,461 patients) showed a significant reduction in HbA1c (weighted mean difference: -0.17%, 95% CI -0.29 to -0.06) and an increase in time in range (TIR) of 70.74 minutes (95% CI 46.73-94.76) compared to standard care (Maiorino et al., 2020). The main barriers included: problems with measurement accuracy in real-world settings, user fatigue leading to low long-term adherence, protection of health data privacy, and lack of standardization and interoperability between devices and EHR (electronic health record) systems. Conclusions: Wearable technologies are becoming an integral part of preventive medicine and chronic disease management. The future lies in blended care models that combine continuous health monitoring with AI predictive algorithms and clinical oversight. Long-term RCT studies (≥12 months) and a clear regulatory framework regarding the accuracy of medical devices, data collection ethics, and legal liability must be established before widespread implementation in healthcare systems.